Table 2. Immunologic characteristics.
| HLAi (n = 50) | ABOi (n = 65) | HLAi+ABOi (n = 5) | |
|---|---|---|---|
| HLA-DSA | |||
| Class I DSA, n (%) | 21 (42.0) | 2 (40.0) | |
| Baseline class I DSA MFI, median (range) | 2118 (1208−6867) | 4715 (1207−8222) | |
| Baseline class I DSA MFI, median (IQR) | 2118 (1909, 3550) | ||
| Pre-transplant class I DSA MFI, median (range) | 410 (0−2997) | 1299 (0−2597) | |
| Class II DSA, n (%) | 28 (56.0) | 3 (60.0) | |
| Baseline class II DSA MFI, median (range) | 3031 (1042−19899) | 2113 (1485−5120) | |
| Baseline class II DSA MFI, median (IQR) | 3031 (2262, 9221) | ||
| Pre-transplant class II DSA MFI, median (range) | 859 (95−2999) | 222 (0−2597) | |
| Direct crossmatch | |||
| FCXM, n (%) | 50 (100.0) | 5 (100.0) | |
| FCXM T cell, n (%) | 22 (44.0) | 4 (80.0) | |
| FCXM T cell MFI ratio, median (range) | 3.30 (1.80, 10.20) | 2.75 (2.30, 4.70) | |
| FCXM B cell, n (%) | 47 (94.0) | 5 (100.0) | |
| FCXM B cell MFI ratio, median (range) | 4.55 (2.00, 78.20) | 13.20 (4.00, 15.50) | |
| CDC-XM, n (%) | 12 (24.0) | 1 (20.0) | |
| CDC-XM T cell, n (%) | 4 (8.0) | 0 (0.0) | |
| CDC-XM B cell, n (%) | 11 (22.0) | 1 (20.0) | |
| ABO isoagglutinin titer, median (range) | |||
| Baseline | 16 (2, 1024) | 32 (2, 1024) | |
| Pre-transplant | 4 (1, 32) | 8 (1, 32) | |
| Desensitization | |||
| Pre-transplant plasmapheresis, n (%) | 35 (70.0)† | 64 (98.5)* | 5 (100.0) |
| Post-transplant plasmapheresis, n (%) | 4 (8.0)† | 0 (0.0)* | 0 (0.0) |
| Number of plasmapheresis | 3.66 ± 2.63‡ | 3.49 ± 2.13‡ | 6.40 ± 2.79*, † |
| Rituximab, n (%) | 45 (90.0) | 65 (100.0) | 5 (100.0) |
| Dose of rituximab, 200 mg | 8 (16.0)† | 51 (78.5)*, ‡ | 0 (0.0)† |
| Dose of rituximab, 500 mg | 37 (74.0)† | 14 (21.5)*, ‡ | 5 (100.0)† |
| IVIG, n (%) | 45 (90.0) | 64 (98.5) | 5 (100.0) |
| Induction therapy | |||
| Basiliximab, n (%) | 23 (46.0)† | 65 (100.0)*, ‡ | 1 (20.0)† |
| Anti-thymocyte globulin, n (%) | 27 (54.0)† | 0 (0.0)*, ‡ | 4 (80.0)† |
*P<0.05 vs. HLAi;
†P<0.05 vs. ABOi;
‡P<0.05 vs. HLAi+ABOi.
Continuous variables are shown as means ± standard deviation or medians (range).
Abbreviations: HLAi, HLA-incompatible; ABOi, ABO-incompatible; DSA, donor-specific antibody; MFI, mean fluorescence intensity; IQR, inter-quartile range; FCXM, flow cytometric cross-match; CDC-XM, complement-dependent cytotoxicity cross-match; IVIG, intravenous immunoglobulin.